Welcome to PsychU!

Pathophysiology Of Agitation Associated With Alzheimer’s Dementia: The Potential Role Of The Norepinephrine, Serotonin, & Dopamine (NSD) Neurotransmitter Systems

Loading Events

Thank You For Attending Today’s Webinar

Please tell us what you thought about today’s presentation by taking the survey below:

Pathophysiology Of Agitation Associated With Alzheimer’s Dementia: The Potential Role Of The Norepinephrine, Serotonin, & Dopamine (NSD) Neurotransmitter Systems

Tau pathology and neurodegeneration in key prefrontal and subcortical brain regions may increase the risk of developing agitation in Alzheimer’s dementia.1 Specifically, agitation in Alzheimer’s dementia may reflect an imbalance between top-down executive control (i.e., hypoactivity in prefrontal regions) and bottom-up emotional drive (i.e., hyperactivity in subcortical regions including the amygdala).1 Moreover, agitation in Alzheimer’s dementia is associated with noradrenergic, serotonergic, and dopaminergic system dysfunction in brain circuits mediating the balance between executive control and emotional drive.2,3 In this webinar, the speakers will review the loss of behavior regulation and the role of the monoamine system in the pathophysiology of agitation associated with Alzheimer’s Dementia.

References

  1. Rosenberg, P.B., et al. Mol Aspects Med. 2015; 43-44: 25-37.
  2. Jacobs, H.I., et al. Mol Psychiatry. 2021; 26(3): 897-906.
  3. 3. Lanctôt, K.L., et al. J Neuropsychiatry Clin Neurosci. 2001; 13(1): 5-21.

Featuring

Laura-Brennan

Laura Brennan, PhD (OPDC)

Clinical Science Liaison

Miranda-Fisher

Miranda Fisher, PhD (OPDC)

Clinical & Scientific Liaison

Speakers Laura Brennan, PhD and Miranda Fisher, PhD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Registration

Log in to register

Already registered?

Already registered?

Use this tool to manage your registration.

Related Resources